Business Description
Autobio Diagnostics Co Ltd
ISIN : CNE100002GC4
Share Class Description:
SHSE:603658: Class ACompare
Compare
Traded in other countries / regions
603658.China IPO Date
2016-09-01Description
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, marketing and service of clinical diagnostic products, including immunoassay, microbiology and biochemical products. It focuses on the common development of both reagents and instruments. Reagents products include immunoassay, biochemistry, microbiology, and IVD subdivision areas, and instruments include both full automation and semi-automation instruments and systems. Geographically it holds a strong distribution network with thousands of distributors in the Chinese market.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.82 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 0.44 | |||||
| Interest Coverage | 54.54 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.92 | |||||
| Beneish M-Score | -2.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.8 | |||||
| 3-Year EBITDA Growth Rate | 13.3 | |||||
| 3-Year EPS without NRI Growth Rate | 12.2 | |||||
| 3-Year FCF Growth Rate | 92.9 | |||||
| 3-Year Book Growth Rate | 41.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.7 | |||||
| 9-Day RSI | 42.41 | |||||
| 14-Day RSI | 41.85 | |||||
| 6-1 Month Momentum % | -25.04 | |||||
| 12-1 Month Momentum % | -14.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.84 | |||||
| Quick Ratio | 2.5 | |||||
| Cash Ratio | 0.22 | |||||
| Days Inventory | 159.41 | |||||
| Days Sales Outstanding | 85.99 | |||||
| Days Payable | 191.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.75 | |||||
| Dividend Payout Ratio | 0.39 | |||||
| 3-Year Dividend Growth Rate | 5.4 | |||||
| Forward Dividend Yield % | 1.75 | |||||
| 5-Year Yield-on-Cost % | 1.81 | |||||
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | 1.16 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.11 | |||||
| Operating Margin % | 27.86 | |||||
| Net Margin % | 26.34 | |||||
| ROE % | 15.37 | |||||
| ROA % | 11.47 | |||||
| ROIC % | 14.66 | |||||
| ROC (Joel Greenblatt) % | 19.41 | |||||
| ROCE % | 15.94 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.53 | |||||
| PE Ratio without NRI | 22.53 | |||||
| Shiller PE Ratio | 42.5 | |||||
| Price-to-Owner-Earnings | 61.05 | |||||
| PEG Ratio | 1.14 | |||||
| PS Ratio | 5.93 | |||||
| PB Ratio | 3.41 | |||||
| Price-to-Tangible-Book | 3.57 | |||||
| Price-to-Free-Cash-Flow | 40.61 | |||||
| Price-to-Operating-Cash-Flow | 17.43 | |||||
| EV-to-EBIT | 20.5 | |||||
| EV-to-EBITDA | 20.5 | |||||
| EV-to-Revenue | 6.01 | |||||
| EV-to-FCF | 41.04 | |||||
| Price-to-Projected-FCF | 2.74 | |||||
| Price-to-DCF (Earnings Based) | 0.72 | |||||
| Price-to-DCF (FCF Based) | 1.3 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.44 | |||||
| Price-to-Graham-Number | 1.89 | |||||
| Price-to-Net-Current-Asset-Value | 7.95 | |||||
| Earnings Yield (Greenblatt) % | 4.88 | |||||
| Forward Rate of Return (Yacktman) % | 16.55 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Autobio Diagnostics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 4,479.319 | ||
| EPS (TTM) (Â¥) | 2.03 | ||
| Beta | -0.1 | ||
| Volatility % | 50.14 | ||
| 14-Day RSI | 41.85 | ||
| 14-Day ATR (Â¥) | 1.223695 | ||
| 20-Day SMA (Â¥) | 46.2505 | ||
| 12-1 Month Momentum % | -14.76 | ||
| 52-Week Range (Â¥) | 44.4 - 81 | ||
| Shares Outstanding (Mil) | 586.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Autobio Diagnostics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Autobio Diagnostics Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Autobio Diagnostics Co Ltd Frequently Asked Questions
What is Autobio Diagnostics Co Ltd(SHSE:603658)'s stock price today?
The current price of SHSE:603658 is ¥45.73. The 52 week high of SHSE:603658 is ¥81.00 and 52 week low is ¥44.40.
When is next earnings date of Autobio Diagnostics Co Ltd(SHSE:603658)?
The next earnings date of Autobio Diagnostics Co Ltd(SHSE:603658) is .
Does Autobio Diagnostics Co Ltd(SHSE:603658) pay dividends? If so, how much?
The Dividend Yield %  of Autobio Diagnostics Co Ltd(SHSE:603658) is 1.75% (As of Today), Highest Dividend Payout Ratio of Autobio Diagnostics Co Ltd(SHSE:603658) was 0.95. The lowest was 0.36. And the median was 0.48. The  Forward Dividend Yield % of Autobio Diagnostics Co Ltd(SHSE:603658) is 1.75%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers